Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.18889 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study.
Travel Med Infect Dis
December 2024
State Key Laboratory of Antibody Research &Development, Hebei Engineering Research Center of Antibody Medicine, North China Pharmaceutical Company New Drug Research and Development Co., Ltd., Shijiazhuang 050015, China. Electronic address:
Background: The combination of passive immune agents (human rabies immune globulin (HRIG) and equine rabies antiserum (ERA)) with vaccines are effective measures for preventing the onset of rabies post exposure. However, ERA and HRIG have potential risks of serum allergic reactions and blood-transmitted infectious diseases. This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone.
View Article and Find Full Text PDFEffects of two different dexamethasone dosing regimens on ventilator-free days and long-term mortality in COVID-19 patients with moderate-to-severe ARDS: the REMED randomized clinical trial.
Eur J Med Res
December 2024
Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, UK.
Background: Dexamethasone 6 mg in patients with severe COVID-19 has been shown to decrease mortality and morbidity. The effects of higher doses of corticosteroid, that would further increase anti-inflammatory effects, are uncertain. The objective of our study was to assess the effect of 20 mg dexamethasone vs.
View Article and Find Full Text PDFTriangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis.
Br J Psychiatry
December 2024
Population Health Sciences, Bristol Medical School, University of Bristol, UK.
Background: Trace amine-associated receptor 1 (TAAR1) agonists offer a new approach, but there is uncertainty regarding their effects, exact mechanism of action and potential role in treating psychosis.
Aims: To evaluate the available evidence on TAAR1 agonists in psychosis, using triangulation of the output of living systematic reviews (LSRs) of animal and human studies, and provide recommendations for future research prioritisation.
Method: This study is part of GALENOS (Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis).
[Surgical treatment for intractable constipation: selection of procedure and perioperative management].
Zhonghua Wei Chang Wai Ke Za Zhi
December 2024
Department of General Surgery, General Hospital of Eastern Theater Command, PLA, Nanjing 210002, China.
When chronic constipation develops to the stage of intractable constipation, the symptoms of constipation in patients are severe and persistent, and drug treatment is often ineffective, so surgical treatment is often considered. The clinical manifestations of patients with intractable constipation are variable, and the underlying pathophysiological changes involve various abnormal and dysfunctional anatomical structure of colorectal and pelvic floor, which are different. For the surgical treatment of intractable constipation, accurate preoperative classification diagnosis is very important, and it is necessary to formulate an exact and effective surgical plan to avoid untargeted empirical treatment.
View Article and Find Full Text PDFHER2DX genomic test in early-stage HER2-positive breast cancer.
ESMO Open
December 2024
Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medicine, University of Barcelona, Barcelona; Reveal Genomics, Barcelona; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain. Electronic address:
Therapies targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer significantly impact patient outcomes, quality of life, and health care systems. While chemotherapy and trastuzumab improve survival in early-stage HER2-positive breast cancer, variability in clinical and biological characteristics leads to different response to therapies and outcomes. Clinical guidelines provide general recommendations, but significant uncertainty persists in identifying an optimal treatment plan for individual patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!